Tvardi Therapeutics (TVRD) Cash from Investing Activities (2013 - 2026)

Tvardi Therapeutics has reported Cash from Investing Activities for 14 years, with the latest figure at $5.0 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 145.72% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 51.5% YoY) and the FY2025 annual result came in at -$10.1 million, down 120.69% from the prior year.
• Cash from Investing Activities held at $5.0 million in Q1 2026 per TVRD's latest filing, from $5.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $44.4 million in Q4 2022 and troughed at -$30.2 million in Q4 2023.
• A 5-year average of $12.7 million and a median of $15.3 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities soared 182.91% in 2022, then sank 167.99% in 2023.
• Over 5 years, Cash from Investing Activities stood at $44.4 million in 2022, then tumbled by 167.99% to -$30.2 million in 2023, then jumped by 116.55% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025, then decreased by 0.48% to $5.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $5.0 million, $5.0 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.